Rohto PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Rohto PharmaceuticalLtd wird ein jährliches Gewinn- und Umsatzwachstum von 9.8% bzw. 7.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 12.8% betragen.

Wichtige Informationen

10.2%

Wachstumsrate der Gewinne

10.2%

EPS-Wachstumsrate

Personal Products Gewinnwachstum	18.2%
Wachstumsrate der Einnahmen	9.0%
Zukünftige Eigenkapitalrendite	13.1%
Analystenabdeckung	Good
Zuletzt aktualisiert	26 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Recent updates

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Sep 22

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Aug 25

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Aug 11

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Jul 11

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Jun 23

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Jun 10

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

May 14

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Apr 03

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Mar 21

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Mar 07

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Feb 26

Gewinn- und Umsatzwachstumsprognosen

TSE:4527 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (JPY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	382,802	42,168	33,678	N/A	9
3/31/2026	357,893	38,088	31,045	N/A	9
3/31/2025	317,896	34,107	23,624	N/A	9
6/30/2024	278,025	30,328	N/A	N/A	N/A
3/31/2024	270,840	30,936	25,333	34,245	N/A
12/31/2023	263,564	30,897	N/A	N/A	N/A
9/30/2023	256,220	29,779	18,967	28,610	N/A
6/30/2023	247,580	28,473	N/A	N/A	N/A
3/31/2023	238,664	26,377	21,016	30,924	N/A
12/31/2022	231,887	25,722	N/A	N/A	N/A
9/30/2022	218,940	23,454	15,347	26,370	N/A
6/30/2022	209,586	23,281	N/A	N/A	N/A
3/31/2022	199,646	21,018	15,922	27,250	N/A
12/31/2021	195,698	22,593	N/A	N/A	N/A
9/30/2021	189,302	21,321	13,846	25,427	N/A
6/30/2021	184,961	19,537	N/A	N/A	N/A
3/31/2021	181,287	16,743	9,704	20,008	N/A
12/31/2020	179,819	13,931	N/A	N/A	N/A
9/30/2020	180,903	14,283	10,794	18,162	N/A
6/30/2020	185,058	15,130	N/A	N/A	N/A
3/31/2020	188,327	15,410	12,607	19,040	N/A
12/31/2019	187,006	11,490	N/A	N/A	N/A
9/30/2019	186,751	9,787	16,076	20,987	N/A
6/30/2019	184,854	8,576	N/A	N/A	N/A
3/31/2019	183,582	9,799	14,828	21,745	N/A
12/31/2018	182,328	10,058	N/A	N/A	N/A
9/30/2018	180,503	10,959	14,057	21,530	N/A
6/30/2018	176,543	10,454	N/A	N/A	N/A
3/31/2018	171,742	9,289	N/A	19,154	N/A
12/31/2017	167,286	11,699	N/A	N/A	N/A
9/30/2017	161,799	11,467	N/A	15,750	N/A
6/30/2017	157,557	10,913	N/A	N/A	N/A
3/31/2017	154,599	10,011	N/A	13,428	N/A
12/31/2016	158,115	9,705	N/A	N/A	N/A
9/30/2016	160,973	8,416	N/A	9,355	N/A
6/30/2016	164,467	9,143	N/A	N/A	N/A
3/31/2016	167,016	9,098	N/A	11,324	N/A
12/31/2015	164,639	10,591	N/A	N/A	N/A
9/30/2015	161,852	9,926	N/A	14,694	N/A
6/30/2015	157,167	9,311	N/A	N/A	N/A
3/31/2015	151,774	8,631	N/A	11,292	N/A
12/31/2014	148,167	6,608	N/A	N/A	N/A
9/30/2014	146,495	8,002	N/A	12,684	N/A
6/30/2014	143,900	7,676	N/A	N/A	N/A
3/31/2014	143,822	8,947	N/A	18,661	N/A
12/31/2013	139,613	9,183	N/A	N/A	N/A
9/30/2013	134,979	9,162	N/A	18,209	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 4527Das prognostizierte Gewinnwachstum (9.8% pro Jahr) liegt über der Sparquote (0.3%).

Ertrag vs. Markt: 4527Die Erträge des Unternehmens (9.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (8.5% pro Jahr).

Hohe Wachstumserträge: 4527Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 4527Die Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt JP (4.3% pro Jahr).

Hohe Wachstumseinnahmen: 4527Die Einnahmen des Unternehmens (7.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 4527Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.4%).

Rohto PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Price target increased by 9.4% to JP¥4,126

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Recent updates

Returns At Rohto PharmaceuticalLtd (TSE:4527) Appear To Be Weighed Down

Upcoming dividend of JP¥16.00 per share

Now 20% undervalued

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2025 Results on Nov 13, 2024

Here's Why Rohto PharmaceuticalLtd (TSE:4527) Has Caught The Eye Of Investors

Rohto Pharmaceutical Co.,Ltd. Just Missed EPS By 6.8%: Here's What Analysts Think Will Happen Next

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Rohto Pharmaceutical Co.,Ltd. Revises Dividend Guidance for the Second Quarter-End and Full Fiscal Year Ending March 31, 2025

Investor sentiment deteriorates as stock falls 16%

Does Rohto PharmaceuticalLtd (TSE:4527) Have A Healthy Balance Sheet?

Final dividend of JP¥15.00 announced

Now 20% undervalued

Calculating The Fair Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2025 Results on Aug 07, 2024

Unpleasant Surprises Could Be In Store For Rohto Pharmaceutical Co.,Ltd.'s (TSE:4527) Shares

Rohto Pharmaceutical Co.,Ltd. agreed to acquire 51% stake in Mono chem-pharm Produkte Gmbh for €30 million.

Now 21% undervalued after recent price drop

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2024

Rohto PharmaceuticalLtd (TSE:4527) Has More To Do To Multiply In Value Going Forward

Rohto Pharmaceutical Co.,Ltd. to Report Q4, 2024 Results on May 13, 2024

Now 21% undervalued after recent price drop

Now 22% undervalued after recent price drop

Rohto Pharmaceutical Co.,Ltd. (TSE:4527), Mitsui & Co., Ltd. (TSE:8031) and others agreed to acquire an 86% stake in Eu Yan Sang International Ltd from Blanca Investments Pte. Ltd., Tower Capital Asia and founding family for approximately SGD 690 million.

These 4 Measures Indicate That Rohto PharmaceuticalLtd (TSE:4527) Is Using Debt Safely

Upcoming dividend of JP¥15.00 per share

Here's Why We Think Rohto PharmaceuticalLtd (TSE:4527) Is Well Worth Watching

Now 21% undervalued after recent price drop

Rohto PharmaceuticalLtd (TSE:4527) Is Paying Out A Larger Dividend Than Last Year

Estimating The Intrinsic Value Of Rohto Pharmaceutical Co.,Ltd. (TSE:4527)

Third quarter 2024 earnings released: EPS: JP¥41.92 (vs JP¥37.02 in 3Q 2023)

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Feb 09, 2024

Price target decreased by 7.5% to JP¥3,814

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Full Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. Declares Dividend for the Second Quarter of Fiscal Ending March 31, 2024, Payable on December 7, 2023

Price target increased by 9.4% to JP¥4,126

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023

Upcoming dividend of JP¥12.00 per share at 0.6% yield

Price target increased by 9.4% to JP¥3,999

Price target increased by 9.0% to JP¥3,884

Investor sentiment improves as stock rises 18%

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023

Price target decreased by 13% to JP¥3,206

Full year 2023 earnings: EPS exceeds analyst expectations

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 28, 2023

Price target increased by 27% to JP¥3,531

Price target increased by 8.4% to JP¥2,870

Upcoming dividend of JP¥12.00 per share at 0.9% yield

Rohto Pharmaceutical Co.,Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Third quarter 2023 earnings: Revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023

Less than half of directors are independent

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rohto Pharmaceutical Co.,Ltd. to Report Q2, 2023 Results on Nov 10, 2022

Upcoming dividend of JP¥20.00 per share

Rohto Pharmaceutical Co.,Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Rohto Pharmaceutical Co.,Ltd. to Report Q1, 2023 Results on Aug 09, 2022

Rohto Pharmaceutical Co.,Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Rohto Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 27, 2022

Consensus forecasts updated

Less than half of directors are independent